NO995033L - 6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser - Google Patents

6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser

Info

Publication number
NO995033L
NO995033L NO995033A NO995033A NO995033L NO 995033 L NO995033 L NO 995033L NO 995033 A NO995033 A NO 995033A NO 995033 A NO995033 A NO 995033A NO 995033 L NO995033 L NO 995033L
Authority
NO
Norway
Prior art keywords
compound
administering
effective amount
therapeutically effective
aminopyrido
Prior art date
Application number
NO995033A
Other languages
English (en)
Norwegian (no)
Other versions
NO995033D0 (no
Inventor
Shripad S Bhagwat
Chih-Hung Lee
Richard J Perner
Yu-Gui Gu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO995033D0 publication Critical patent/NO995033D0/no
Publication of NO995033L publication Critical patent/NO995033L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO995033A 1997-04-16 1999-10-15 6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser NO995033L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83439397A 1997-04-16 1997-04-16
PCT/US1998/004127 WO1998046603A1 (en) 1997-04-16 1998-04-16 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds

Publications (2)

Publication Number Publication Date
NO995033D0 NO995033D0 (no) 1999-10-15
NO995033L true NO995033L (no) 1999-12-15

Family

ID=25266829

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995033A NO995033L (no) 1997-04-16 1999-10-15 6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser

Country Status (20)

Country Link
EP (1) EP0979230A1 (ja)
JP (1) JP2001520649A (ja)
KR (1) KR20010006453A (ja)
CN (1) CN1259948A (ja)
AR (1) AR012435A1 (ja)
AU (1) AU744528B2 (ja)
BG (1) BG103861A (ja)
BR (1) BR9809088A (ja)
CA (1) CA2287465A1 (ja)
CO (1) CO4940439A1 (ja)
HU (1) HUP0001402A3 (ja)
IL (1) IL131892A0 (ja)
NO (1) NO995033L (ja)
NZ (1) NZ337844A (ja)
PL (1) PL336262A1 (ja)
SK (1) SK142099A3 (ja)
TR (1) TR199902456T2 (ja)
TW (1) TW458977B (ja)
WO (1) WO1998046603A1 (ja)
ZA (1) ZA982912B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057040A1 (en) * 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
DK1361880T3 (da) * 2001-02-12 2006-01-23 Hoffmann La Roche 6-substituerede pyrido-pyrimidiner
WO2006053250A2 (en) 2004-11-12 2006-05-18 Trustees Of Tufts College Lipase inhibitors
US20100063032A1 (en) * 2007-03-28 2010-03-11 Debenham John S Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
MX2015004151A (es) * 2012-10-05 2015-07-06 Rigel Pharmaceuticals Inc Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8).
WO2017205848A1 (en) * 2016-05-27 2017-11-30 Legacy Emanuel Hospital & Health Center Methanocarba derivatives of pseudoribose that inhibit adenosine kinase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774094A (en) * 1953-01-02 1957-05-08 Wellcome Found Improvements in or relating to pyrimidine compounds
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds

Also Published As

Publication number Publication date
ZA982912B (en) 1998-10-09
JP2001520649A (ja) 2001-10-30
HUP0001402A3 (en) 2001-01-29
BG103861A (en) 2000-06-30
TR199902456T2 (xx) 2000-07-21
SK142099A3 (en) 2000-05-16
CN1259948A (zh) 2000-07-12
EP0979230A1 (en) 2000-02-16
AU7098198A (en) 1998-11-11
AU744528B2 (en) 2002-02-28
KR20010006453A (ko) 2001-01-26
PL336262A1 (en) 2000-06-19
TW458977B (en) 2001-10-11
CO4940439A1 (es) 2000-07-24
NZ337844A (en) 2001-11-30
WO1998046603A1 (en) 1998-10-22
IL131892A0 (en) 2001-03-19
BR9809088A (pt) 2000-08-01
NO995033D0 (no) 1999-10-15
HUP0001402A2 (hu) 2000-10-28
AR012435A1 (es) 2000-10-18
CA2287465A1 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
EA200100135A1 (ru) Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
NO331068B1 (no) Benzazepinderivater for behandling av nevrologiske forstyrrelser.
NO175592C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive xantiner
WO1996013512B1 (en) L-ribofuranosyl nucleosides
EP1259487B8 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
WO2001098277A3 (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
WO2003048164A3 (en) Adenosine a2a receptor antagonists
RU94022743A (ru) Амидо- или карбамидо-производные, обладающие антигиперхолестериновой активностью, и фармацевтическая композиция на их основе
NO995036L (no) 5,7-disubstituerte 4-aminopyrido[2,3-d]pyrimidinforbindelser og deres anvendelse som adenosinkinaseinhibitorer
CA2212326A1 (en) O-carbamoyl-(d)-phenylalanilol compounds and process for preparing the same
NO20001169L (no) 6,9-bro erythromycinderivater
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
NO20002099L (no) 6,11-bro-erytromycinderivater
TW372237B (en) 1-2-4 triazolo[1,5-a]pyrimidines, pharmaceutical compositions containing them for treatment and/or prophylaxis of seizures, neurological disorders and/or conditions in which there is neurological damage, and processes for their preparation
WO2000026224A3 (en) Novel macrolide antibiotics
DE69524428T2 (de) Dihydrobenzofuran und verwandte verbindungen als entzündungshemmende mittel
CA2107223A1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
NO995033L (no) 6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
CA2597327A1 (en) Antibiotic macrolides
NO995035L (no) 5,6,7-trisubstituerte-4-aminopyrido[2,3- D]pyrimidinforbindelser
ATE144423T1 (de) Therapeutische benzazepin verbindungen
ES2173988T3 (es) Derivados de furano para inhibir la neumonia por pneumocistis carinii, giardia lamblia y criptosporidium parvum.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application